NuCana Competitors

NuCana (NASDAQ:NCNA) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares NuCana and Esperion Therapeutics' top-line revenue, earnings per share and valuation.

NuCana has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NuCana and Esperion Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NuCana and Esperion Therapeutics, as reported by MarketBeat.

NuCana presently has a consensus price target of $17.50, indicating a potential upside of 327.87%. Esperion Therapeutics has a consensus price target of $50.60, indicating a potential upside of 86.44%. Given NuCana's stronger consensus rating and higher possible upside, analysts plainly believe NuCana is more favorable than Esperion Therapeutics.

Institutional & Insider Ownership

84.1% of NuCana shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

NuCana has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Summary

NuCana beats Esperion Therapeutics on 10 of the 14 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares ORIC Pharmaceuticals and NuCana's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings for ORIC Pharmaceuticals and NuCana, as provided by MarketBeat.com.

ORIC Pharmaceuticals presently has a consensus target price of $43.7143, indicating a potential upside of 107.57%. NuCana has a consensus target price of $17.50, indicating a potential upside of 327.87%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than ORIC Pharmaceuticals.

Valuation and Earnings

This table compares ORIC Pharmaceuticals and NuCana's gross revenue, earnings per share (EPS) and valuation.

Institutional & Insider Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 84.1% of NuCana shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ORIC Pharmaceuticals beats NuCana on 4 of the 6 factors compared between the two stocks.

Humanigen (NASDAQ:HGEN) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

30.2% of Humanigen shares are held by institutional investors. Comparatively, 84.1% of NuCana shares are held by institutional investors. 37.5% of Humanigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Humanigen and NuCana's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Humanigen and NuCana, as provided by MarketBeat.

Humanigen presently has a consensus target price of $29.8333, indicating a potential upside of 106.03%. NuCana has a consensus target price of $17.50, indicating a potential upside of 327.87%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than Humanigen.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its stock price is 179% less volatile than the S&P 500. Comparatively, NuCana has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Earnings & Valuation

This table compares Humanigen and NuCana's gross revenue, earnings per share (EPS) and valuation.

Summary

NuCana beats Humanigen on 5 of the 7 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Earnings & Valuation

This table compares Karyopharm Therapeutics and NuCana's gross revenue, earnings per share (EPS) and valuation.

NuCana has lower revenue, but higher earnings than Karyopharm Therapeutics. NuCana is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Karyopharm Therapeutics and NuCana, as provided by MarketBeat.

Karyopharm Therapeutics presently has a consensus target price of $29.8750, indicating a potential upside of 214.81%. NuCana has a consensus target price of $17.50, indicating a potential upside of 327.87%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than Karyopharm Therapeutics.

Profitability

This table compares Karyopharm Therapeutics and NuCana's net margins, return on equity and return on assets.

Institutional and Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 84.1% of NuCana shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Karyopharm Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, NuCana has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Karyopharm Therapeutics beats NuCana on 7 of the 13 factors compared between the two stocks.

NuCana (NASDAQ:NCNA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

This table compares NuCana and Lexicon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Lexicon Pharmaceuticals has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for NuCana and Lexicon Pharmaceuticals, as provided by MarketBeat.com.

NuCana currently has a consensus target price of $17.50, indicating a potential upside of 327.87%. Lexicon Pharmaceuticals has a consensus target price of $9.40, indicating a potential upside of 87.25%. Given NuCana's stronger consensus rating and higher possible upside, equities analysts plainly believe NuCana is more favorable than Lexicon Pharmaceuticals.

Profitability

This table compares NuCana and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.1% of NuCana shares are held by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

NuCana has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500.

Summary

Lexicon Pharmaceuticals beats NuCana on 7 of the 13 factors compared between the two stocks.

NuCana (NASDAQ:NCNA) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

This table compares NuCana and Intercept Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

NuCana has higher earnings, but lower revenue than Intercept Pharmaceuticals. NuCana is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for NuCana and Intercept Pharmaceuticals, as provided by MarketBeat.com.

NuCana currently has a consensus target price of $17.50, indicating a potential upside of 327.87%. Intercept Pharmaceuticals has a consensus target price of $50.6957, indicating a potential upside of 145.74%. Given NuCana's stronger consensus rating and higher possible upside, equities analysts plainly believe NuCana is more favorable than Intercept Pharmaceuticals.

Profitability

This table compares NuCana and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.1% of NuCana shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

NuCana has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Summary

NuCana beats Intercept Pharmaceuticals on 7 of the 13 factors compared between the two stocks.